A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)

被引：0
|
作者：
Zhang, L. [1 ]
Fang, W. F. [1 ]
Zhao, S. [1 ]
Yu, Y. [2 ]
Yong, T. X. [3 ]
Dong, X. [4 ]
Zhuang, W. [5 ]
Hu, Y. [6 ]
Luo, F. [7 ]
Wang, Q. [8 ]
Chu, Q. [9 ]
Fu, Z. [10 ]
Yao, Y. [11 ]
Ma, X. [12 ]
Ding, C. [13 ]
Hao, J. [14 ]
Yang, X. [14 ]
Wan, X. [14 ]
Li, M. [14 ]
Yang, Y. [14 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[3] Shandong Canc Hosp & Inst, Dept Resp Med, Jinan, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Oncol, Wuhan, Peoples R China
[5] Fujian Prov Canc Hosp, Dept Resp Med, Fuzhou, Peoples R China
[6] Hubei Canc Hosp, Dept Oncol, Wuhan, Peoples R China
[7] Sichuan Univ, West China Hosp, West China Sch Med, Lung Canc Ctr, Chengdu, Peoples R China
[8] Jiangsu Prov Hosp Tradit Chinese Med TCM, Dept Resp Med, Nanjing, Peoples R China
[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[10] Wuhan Univ, Renmin Hosp, Hubei Gen Hosp, Canc Ctr, Wuhan, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China
[12] Qingdao Univ, Affiliated Qingdao Cent Hosp, Canc Ctr, Qingdao, Peoples R China
[13] Fourth Hosp Hebei Med Univ North Gate, Dept Resp Med, Shijiazhuang, Hebei, Peoples R China
[14] CSPC Pharmaceut Grp Co Ltd, Clin Div, Shijiazhuang, Hebei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614MO
引用
收藏
页码：S1624 / S1625
页数：3
相关论文
共 50 条
  • [1] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [2] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [3] Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer
    Aredo, Jacqueline V.
    Urisman, Anatoly
    Gubens, Matthew A.
    Mulvey, Claire
    Allen, Greg M.
    Rotow, Julia K.
    Kerr, Daniel Lucas
    Chakrabarti, Turja
    Bacaltos, Bianca
    Gee, Megan
    Jones, Kirk
    Aisner, Dara L.
    Patil, Tejas
    Schenk, Erin Lynn
    Bivona, Trever G.
    Riess, Jonathan W.
    Coleman, Melissa
    Kratz, Johannes Ruediger
    Jablons, David
    Blakely, Collin M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [5] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [6] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu
    Fachao Xie
    Fang Wang
    Liwu Fu
    Journal of Hematology & Oncology, 15
  • [7] Phase I/II Study Exploring Safety and Efficacy of Apl-101 Plus Frontline Osimertinib in EGFR-mutated Metastatic Non-small Cell Lung Cancer
    Patel, B.
    Wu, N.
    Myles, S.
    Turlington, D.
    Yu, P.
    Saha, G.
    Rohatgi, A.
    Herzog, B. H.
    Ward, J. P.
    Baggstrom, M. Q.
    Waqar, S. N.
    Morgensztern, D.
    Govindan, R.
    Devarakonda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S350 - S350
  • [8] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [9] A prospective observational multicenter cfDNA study in EGFR-mutated non-small cell lung cancer treated with osimertinib
    Osuga, Mitsuo
    Tamiya, Akihiro
    Mizumori, Yasuyuki
    Isa, Shunichi
    Fujita, Yuka
    Kozuki, Toshiyuki
    Shinohara, Tsutomu
    Yanai, Hidetoshi
    Nakatomi, Katsumi
    Oki, Masahide
    Mori, Masahide
    Kuwako, Tomohito
    Yamazaki, Koji
    Tamura, Atsuhisa
    Ando, Masahiko
    Koh, Yasuhiro
    CANCER SCIENCE, 2024, 115 : 845 - 845
  • [10] Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
    Saito, Ryota
    Sugawara, Shunichi
    Ko, Ryo
    Azuma, Koichi
    Morita, Ryo
    Maemondo, Makoto
    Oizumi, Satoshi
    Takahashi, Kazuhisa
    Kagamu, Hiroshi
    Tsubata, Yukari
    Seike, Masahiro
    Kikuchi, Toshiaki
    Okamoto, Isamu
    Satoshi, Morita
    Asahina, Hajime
    Tanaka, Kentaro
    Sugio, Kenji
    Kobayashi, Kunihiko
    EUROPEAN JOURNAL OF CANCER, 2023, 185 : 83 - 93
12345